MedTrace Logo

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy

NCT01434134 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2014-10-22

No results posted yet for this study

Summary

Women treated for breast cancer are at increased risk for cardiovascular disease, including heart failure. In this study, by using magnetic resonance imaging (MRI), the investigators want to assess if heart failure medications such as beta blockers and angiotensin receptor blockers can prevent cardiac dysfunction during early breast cancer therapy.

Conditions

Interventions

DRUG

Metoprolol

Tablet, target dose 100 mg once daily

DRUG

Placebo

Tablet, target dose 100 mg once daily

DRUG

Candesartan

Tablet, target dose 32 mg once daily

DRUG

Placebo

Tablet, 32 mg once daily

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Norwegian Cancer Society

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Stein Vaaler · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Norway

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01434134 on ClinicalTrials.gov